Pfizer CEO touts $80 billion in deals – but the ‘real test’ is yet to come

Pfizer (PFE) beat third-quarter expectations and raised its forecast Tuesday, but one portfolio manager says “the real test is yet to come” for the S&P 500 pharmaceutical giant. David Wagner, portfolio manager at Aptus Capital Advisors, noted that the new products now carry the company’s core business, rather than the former high-flying Covid products, Paxlovid and Comirnaty. Additionally, cost reductions are…